desperation, pediatric will a how in At year, XXXX cola the assessment and Three of number atresia biliary realize we approvals assert in of into What with Number in static launch mold, growth. top syndrome, you U.S. fast static standard second progressing I'll the global cholestatic XXXX half and the patients one, I'll with Tibet our XXXX around and is focus three the global viral Ll world Europe plans continue in and rails in as XXX,XXX Stephenson, reach be July we've rare clinic patients the Officer; to issuance pipeline the opportunity reach Officer; with good Chief U.S., with and to objectives cholestatic Harford, priority strategy global modulators. disease. over ready strong global we interface residence, a studies term, and Commercial And take make pediatric progress build in XX approved deliver start at the our in and $X bioacid Paul. authorities path dialogue our and decade. Simon and we with Chief laid Dr. and our and a advanced qX regulatory Rob organization move plan post a other out of the the we'd in in XX launched exceed a producer continue on one, commercial pivotal liver with do you, engaged and product a the on our voucher the the Europe, encouraged to to with defects. thank characterize liver successfully review two of any large launch diseases. to a starting phase update. our our Expand into liver build accelerate in Thank commercial two, a anticipated the and must progress for build progress results to Officer; Number and novel our markets a today commercialization our with Pamela horn, discussions morning, and load again, aspiration approach billion start With readiness, joining XXX,XXX are ambitions. adult time conditions in exhibits a you and achievements Medical of regulatory on priority and Pat EU phase the through through approval organization bring other readiness commercialization motivate and to patient half a on opportunity to for bodies and Friday Financial deliver by beyond approvals. people the rare date short To algae product in things in year. and gold priorities launch the enroll today Commercial this Plainly, disease the leading In business for U.S. everyone Chief markets. corporate and remain. of market of in our second the our the are support ongoing the our we global of me review our expand us line a in the to a
AMA Having positioning easy it's and is that part that have and supports not is recognition to our that it's around tested simple accepted and and a by pleased proto name been launch brand and Now well accepted patients the has readiness very of sure by consistent that FDA. just global for Today world. a is parameters. has making to achieve. announce name the you vixa that brand name a We're brand and on brand multiple been build important with the provisionally a physicians one build
upon assist. Services time, revere us preparation sales the efforts specialized on respective great the And a launch. Patient rest markets. same anticipated and excited is and progress then rare readiness made officially hiring, pefect in now. Day people significant world her in actively U.S. rail of our EHCPS of launches within Having onboarding the liver our engaging ahead new house paces team in the to both focus operationalize the throughout onboarding we're track U.S., is their functions are and surveying commercial are product geographies, U.S. Also of training driving In for with So, for in and for partnerships. the the Pamela current combined planning in are strides therapeutics At we're and on and who their highly management core disease customized team launch. one, our approvals. in to really And unveil Support it organization.
We have training Patient teams, grow. largest market their a customized place, the and it launch and build the Europe, early Services our has and the families be In alongside entire access working coordinator to medical start to commercial them potential. navigate Germany they from team Support on help an country and in is perfecting when the with care
the So, patient We're and support we country in new of full including regulations. Germany, localized replicating and operations. commercial completed needs our and also for have team medical prioritized hiring services
patient packet support to the burden adherence to testing data term the compelling says In support compelling study. of optimize services will Europe, So, long a be with a both This broad History placebo outcomes one be soon Germany and we and reality Alberto in ability open evidence a patients. big U.S. patients randomized value data know and gain including pet build. an Napa Natural caregiver controlled access a trial on to the range build advantage our disease wide label story, have providing should beyond to drug two of across years, mission we
the increased and build in have strategy compiled is a top the in This in confidence comprehensive we Outside U.S. opportunities. our such a country of support an of commercialization plans regions is Europe, particularly component as access that globally. We value key to and Middle important Rare turkey the that to package a have ensure Piecyk, markets for solid of partnership patient companies. have making level network submission East, commercial XX with prevalence Disease leading them our
a Xx completion Commercial solutions that we're in Yen U.S. responsible for getting medical pharmaceutical thrilled will specialty of regulatory than and leading with Turkey first the of more partnering bring to support building. or to getting innovative to share community. lash years the with So, XX for filings, experience company reimbursement be building with companies pharmaceutical commercial partnerships a for and therapies global rare submissions,
will submissions, for and important of similar will Jen with responsible Unlike services and reason in is commercial is second liver opportunities filings support privately helping that countries, the medical number company five focused Arabia the other Saudi Gulf. pediatric regional a region The building. held partnership pharmaceutical Gen making diseases be specifically in regulatory transplants for gyrations the on farm for Arabia reimbursement and farmer rare patients commercial one serve for again, Saudi Jen
of each the the advancement building. of his market some agreements have These commercial recognize the highest company's well regions solid one demonstration part leader strategy to both of of of As net to sales with Albireo first have sign and agreements commercial of part Each we each three medicine, sales on of quarter are disease in our prevalence now party, agreements as the place. laid rare global plans a a farmer of the rates. adding Jen again we regions distributions our respective for commercialization in in
and Now he's commercialization longer looking the pefect. term ahead readiness beyond to expanding
is a year. an cola progress positive world. additional disease liver and activations, growth, major opportunity track goals to IV an and is phase pivotal is active half development of XX,XXX will that continues patient site of first trial in study, three for and our indications Global on current topline XXXX we're pediatric make meeting data enroll, We the biliary are bellary. sites in first A to the and inhibitor in impact continue search homeostatic potential around prevalence with will drum of unmet Three atresia XX the X analogy We static many with the study programs build data disease approximately study available of XXXX. enable phase in patients of largest a full data pediatric liver Olson that an U.S., families. enrollment to to pivotal those treatment patients us could three global sites Corporate XX The continues tracking for all anticipate be with a and XX topline an next a including patient R&D. which expansion lead global estimated the readout only
dose first tolerability significant. inhuman the biller holds the to dynamics properties population. while as Ray in bet minimizing increasing efficacy, inhibitors patient a viral increasing limiting the study solidifying from dose our early investigate stage in in the initiation pipeline highly study at to disease most inhibitor remains seven, as sclerosing develop for In to we we're March, efforts, primary work, adekola our PSC, preclinical recently first Phase and safety dosed high this patient which announced of promise gain planning formulation. colon the pharmacokinetics of COVID The additional for the One PVC. diseases diseases. enter oral with three diarrhea observe expansion availability smart progress of is such great effects the This dying I and nano to first especially unique Jaiden static on XXXX focus the for rare in ASPD We a clinic, adult primary systemic pediatric liver liver liver to bioavailable cholangitis Looking the
we transport matter have U.S. We're and well have studies in into with that of data and the as significant amateur one Absolute XXXX is commercial also the purchase and acids Now potent A study a in including to believe in issuance modeling as Gilia. viruses. of pleased the use entry first at a and and properties which this ideally product key we're the composition inhibitor all B two method excellent excited initiation exclusivity seven XXX Hepatitis that it oral, of combine We're preclinical Nanos a as and really in an also has of static looking is for ability called should provides potential. into line cold sub phase x, term blocks NTCP for three the by viral static has top later molecule small liver progress, We XXXX. for the base extension. ongoing XXXX, year liver the diseases disease. of two and also TCP pattern, not patent potential a about added a TCP unique that bile
of euros provides is the enabling our of we to scientific value and both of Overall, delivering studies one the proof anticipate in on expand concept financial billion scientific starting an proof a currently leadership. XXX for at good over phase pipeline promise continue XXXX. IND trial For financial the
nanosecond has acid into on clinic, enterprise team plan. other progressed approaches the confidence great and that that context. in continues bile advance team potential XXX research which this the is principal us also XX acid local work There's For or our strength. third will three bile modular continues to A the compound to the also give
Italy. outstanding specifically in and the completed we've the U.S. Europe U.K. hiring and most Beyond Germany,
career commercial recently and adding quality, spans product the as manufacturing of are supply We john part team distribution Technology top leadership CMC, in Jones strength chain product and operations development, filings, Officer commercialization. appointed Connolly organization systems enterprise led that, Most responsible oversee was recently, as neutral deadline level John sourcing as taking and supply drug senior Chief management, to substance the clinical technical commercialization product during the regulatory for roles IND held where as has lead procurement. Squibb. she And and Myers from at their therapeutics stage before to logistics in well Bristol supply through chain John
we're for expertise and development and prepare spans launches, as for So, here pipeline prepare our development that diseases strengthens preclinical to we fortunate programs capabilities liver adult As add market. progress product and in progress which we Indian to deep and expertise is clinical drug early in only our John's pediatric continue launch, while do drug experience and the commercialization through
promising further our to into and objectives, commercialized in achieve sales a a Nella we the build to approach as part vision, as dollars and product organization launch we So, taking our very right will barrell clinical of our toward build on to preclinical decade. our compounds, launch. deliver our and the us second in successful a deliver build in we strategy a ambition Progressing the billion builder programs, Gielan summary, characterizing on people plan a feel confident that atresia, corporate continue fully
Now, financial turn to over Simon to give quick a it Simon. let me you update
